Ben Goertzel’s scientific contributions

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


Figure 1A Mean MMSE Scores for All Subjects. Average MMSE scores for ReBuilder study subjects and the Bernick group over the course of 12 months.
Figure 1B Mean MMSE Scores for Mild Subjects. Average MMSE scores for mild subjects in the ReBuilder study compared to the Bernick group over 12 months.
Figure 1C Mean Mini Mental State Exam (MMSE) Scores for Moderate Subjects. Average MMSE score for moderate subjects in the ReBuilder study compared to the Bernick group.
Figure 1D Mean Mini Mental State Exam (MMSE) Scores for Female Subjects. Female subjects taking ReBuilder during our pilot study were able to maintain a MMSE score closer to the baseline than those in the Bernick study.
Figure 1E Mean Mini Mental State Exam (MMSE) Scores for Male Subjects. Male subjects taking ReBuilder during our pilot study took 6 months to see an improvement in their MMSE score. BY Q4 the men rebounded back to their baseline score.

+10

Botanical Mixture Stabilizes Cognitive Function in Patients with Mild and Moderate Alzheimer’s Disease
  • Article
  • Full-text available

August 2018

·

3,463 Reads

·

·

Willam R. Shankle

·

[...]

·

Cristina L. Rizza

Context: Currently, there is no treatment that can stop the progression of Alzheimer’s disease. We have used transgenic Drosophila melanogaster models and machine learning to develop an eight component botanical mixture (Geneaire™ ReBuilder™) that targets multiple genetic pathways involved in brain aging and dementia that are homologous between Drosophila and humans. Objective: To test the effects of ReBuilder on the cognitive function of subjects diagnosed with mild or moderate Alzheimer’s disease. Methods: We recruited 50 subjects with mild to moderate AD to participate in a double-blind, placebo-controlled clinical study. During the 12-month pilot study, the subjects were evaluated quarterly on the Mini Mental State Exam (MMSE), Alzheimer’s Disease Cooperative Study’s Activities of Daily Living (ADCS-ADL), and the Clinical Dementia Rating Sum of Boxes (CDR-SB). Results: The addition of ReBuilder to subjects’ existing Namenda and Exelon regimens stabilized cognitive decline in patients with mild AD and slowed cognitive decline in patients with moderate AD. Conclusions: These results were observed in both sexes and in all ages tested. Importantly, no adverse side effects attributable to ReBuilder were reported. The results of this clinical pilot warrant further study of ReBuilder in AD.

Download

Citations (1)


... Our own work with Genescient on analyzing DNA, RNA and other data from their long-lived flies is largely inspired by the "broad based aging trigger" philosophy -the hope is that a relatively small number of pathways can be found that are heavily causal for aging in flies, and that transfer learning can then help us port this conclusion to humans, leading to impactful human longevity therapeutics. However, the same datasets can also be helpful for understanding age-associated disease, and in our prior work we have leveraged Methuselah fly genomics to better understand the pathways behind Parkinsons and Alzheimers in humans (Matsagas et al 2017). ...

Reference:

Leveraging Algorithmic and Human Networks to Cure Human Aging: Holistic Understanding of Longevity via Generative Cooperative Networks, Hybrid Bayesian/Neural/Logical AI and Tokenomics-Mediated Crowdsourcing
Multipath Natural Product Supplement Suppresses Dementia Symptoms in Amyloid-β and Tau Transgenic Drosophila